Natera Inc

Market Summary

USD58.15+0.21

Market Closed

0.36%

NTRA Alerts

3 major insider sales recently.
Big jump in Revenue (Y/Y)
Losses in recent quarter

NTRA Stock Price

View Fullscreen

NTRA RSI Chart

NTRA Alerts

3 major insider sales recently.
Big jump in Revenue (Y/Y)
Losses in recent quarter

NTRA Valuation

Market Cap

6.9B

Price/Earnings (Trailing)

-13.86

Price/Sales (Trailing)

EV/EBITDA

-13.43

Price/Free Cashflow

-22.22

NTRA Price/Sales (Trailing)

NTRA Profitability

EBT Margin

-50.45%

Return on Equity

-63.64%

Return on Assets

-34.52%

Free Cashflow Yield

-4.5%

NTRA Fundamentals

NTRA Revenue

Revenue (TTM)

988.7M

Revenue Y/Y

27.38%

Revenue Q/Q

2.64%

NTRA Earnings

Earnings (TTM)

-499.3M

Earnings Y/Y

10.25%

Earnings Q/Q

1.6%

Price Action

Last 7 days

-0.5%

Last 30 days

40.7%

Last 90 days

7.3%

Trailing 12 Months

50.0%

How does NTRA drawdown profile look like?

NTRA Financial Health

Current Ratio

4.37

NTRA Investor Care

Shares Dilution (1Y)

22.29%

Diluted EPS (TTM)

-4.52

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	867.8M	931.0M	988.7M	0
2022	667.3M	723.5M	776.0M	820.2M
2021	449.3M	504.9M	564.8M	625.5M
2020	329.5M	341.6M	361.9M	391.0M
2019	262.1M	273.4M	286.1M	302.3M
2018	222.6M	233.4M	242.7M	257.7M
2017	204.6M	204.9M	206.9M	209.6M
2016	204.8M	211.7M	220.7M	217.1M
2015	179.4M	188.7M	187.3M	190.4M
2014	81.2M	107.2M	133.3M	159.3M
2013	0	0	0	55.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for NTRA

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 29, 2023	chapman rowan e	sold	-111,831	55.9714	-1,998	-
Nov 21, 2023	marcus gail boxer	sold	-54,313	54.3136	-1,000	-
Nov 20, 2023	chapman steven leonard	sold	-141,130	55.00	-2,566	ceo and president
Nov 02, 2023	sheena jonathan	sold	-201,150	40.23	-5,000	-
Nov 02, 2023	sheena jonathan	sold	-20,236	40.472	-500	-
Nov 02, 2023	sheena jonathan	sold	-20,115	40.23	-500	-
Oct 27, 2023	healy james	acquired	16,869	42.6	396	-
Oct 27, 2023	rosenman herm	acquired	19,340	42.6	454	-
Oct 27, 2023	baynes roy d.	acquired	13,717	42.6	322	-
Oct 23, 2023	sheena jonathan	sold	-20,018	40.037	-500	-

Which funds bought or sold NTRA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Dec 06, 2023	CITIGROUP INC	added	55.86	2,377,000	8,072,710	0.01%
Nov 27, 2023	TRUST CO OF VERMONT	unchanged	-	-463	4,646	-%
Nov 27, 2023	BANQUE PICTET & CIE SA	added	7.33	-155,290	6,321,110	0.07%
Nov 27, 2023	AllSquare Wealth Management LLC	unchanged	-	-283	4,425	-%
Nov 24, 2023	DEUTSCHE BANK AG\	reduced	-92.63	-3,775,930	271,076	-%
Nov 22, 2023	Polar Capital Holdings Plc	reduced	-38.34	-316,342	403,826	-%
Nov 22, 2023	Public Sector Pension Investment Board	sold off	-100	-4,622,700	-	-%
Nov 22, 2023	Graham Capital Management, L.P.	sold off	-100	-521,537	-	-%
Nov 21, 2023	Walleye Capital LLC	new	-	5,514,740	5,514,740	0.01%
Nov 21, 2023	COMERICA BANK	new	-	7,936	7,936	-%

Latest Funds Activity

Are funds buying NTRA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NTRA

No. of Funds

Schedule 13G FIlings of Natera Inc

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 06, 2023	blackrock inc.	4.9%	5,509,188	SC 13G/A
Feb 14, 2023	alger associates inc	8.2%	8,972,721	SC 13G/A
Feb 09, 2023	vanguard group inc	9.01%	9,945,514	SC 13G/A
Feb 03, 2023	blackrock inc.	5.1%	5,566,743	SC 13G
Jan 23, 2023	jpmorgan chase & co	5.6%	6,211,632	SC 13G/A
Jun 09, 2022	blackrock inc.	4.9%	4,706,415	SC 13G
Feb 14, 2022	alger associates inc	7.2%	6,805,028	SC 13G/A
Feb 03, 2022	blackrock inc.	7.4%	7,010,757	SC 13G/A
Jan 24, 2022	jpmorgan chase & co	5.3%	5,025,967	SC 13G
Feb 16, 2021	alger associates inc	7.28%	6,217,680	SC 13G

Recent SEC filings of Natera Inc

View All Filings

Date Filed	Form Type	Document
Dec 08, 2023	144	Notice of Insider Sale Intent
Dec 08, 2023	4	Insider Trading
Dec 01, 2023	4	Insider Trading
Nov 29, 2023	144	Notice of Insider Sale Intent
Nov 22, 2023	4	Insider Trading
Nov 22, 2023	4	Insider Trading
Nov 21, 2023	144	Notice of Insider Sale Intent
Nov 20, 2023	144	Notice of Insider Sale Intent
Nov 09, 2023	10-Q	Quarterly Report
Nov 08, 2023	8-K	Current Report

Peers (Alternatives to Natera Inc)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	160.7B	29.6B	10.51%	-19.98%	27.16	5.44	-5.39%	-12.54%
IDXX	44.1B	3.6B	24.23%	23.99%	53.65	12.3	7.43%	22.86%
A	37.3B	7.0B	16.28%	-18.61%	32.89	5.33	5.03%	-14.68%
DGX	15.2B	9.3B	1.84%	-9.68%	19.95	1.64	-9.69%	-38.22%
EXAS	11.7B	2.4B	2.99%	40.82%	-41.48	4.86	19.99%	60.62%
MID-CAP
CRL	10.5B	4.2B	16.20%	-2.67%	22.08	2.49	11.49%	8.84%
MEDP	8.7B	1.8B	2.84%	34.94%	31.81	4.88	29.62%	20.49%
NTRA	6.9B	988.7M	40.66%	50.03%	-13.86	7	27.41%	8.51%
NEOG	3.9B	919.1M	17.21%	17.06%	-147.97	4.28	73.02%	-172.93%
GH	3.0B	535.8M	8.75%	-45.64%	-7.02	5.66	24.38%	26.34%
SMALL-CAP
CDNA	531.2M	297.1M	54.98%	-22.82%	-5.87	1.79	-6.74%	-21.60%
ACRS	71.5M	21.4M	-81.47%	-93.49%	-0.62	3.34	-8.80%	-39.66%
AWH	31.2M	9.2M	-11.33%	-33.68%	-1.76	3.4	16.43%	48.38%
APDN	12.0M	13.4M	-4.35%	-39.31%	-1.21	0.9	-26.43%	-20.54%
BIOC	120.4K	-	-82.76%	-93.43%	0	0.76	-57.78%	-93.13%

Natera Inc News

Latest updates

Insider Monkey • 10 Dec 2023 • 04:59 pm • 9 hours ago

12 Best Genomics Stocks To Buy Now

MarketBeat • 07 Dec 2023 • 11:02 pm • 3 days ago

GCM Grosvenor Holdings LLC Makes New Investment in Natera, Inc ...

DirectorsTalk Interviews • 07 Dec 2023 • 01:08 pm • 3 days ago

Natera, Inc. - Consensus 'buy' rating and 23.3% Upside Potential

Marketscreener.com • 07 Dec 2023 • 12:33 pm • 3 days ago

Natera Presents New Signatera MRD Data across Breast Cancer ...

Defense World • 03 Dec 2023 • 07:48 am • 7 days ago

Comparing Natera (NASDAQ:NTRA) and CannLabs (OTCMKTS ...

Yahoo Finance • 02 Dec 2023 • 12:06 pm • 8 days ago

Insider Sell Alert: Director Rowan Chapman Sells Shares of Natera ...

Nasdaq • 01 Dec 2023 • 09:00 pm • 9 days ago

Validea Detailed Fundamental Analysis - NTRA

MarketBeat • 01 Dec 2023 • 04:22 pm • 9 days ago

Natera, Inc. (NASDAQ:NTRA) Shares Sold by Eagle Health ...

Securities.io • 18 Nov 2023 • 08:00 am • 22 days ago

Best Early Cancer Detection And Liquid Biopsy Stocks ([month] [year])

Business Wire • 14 Nov 2023 • 08:00 am • 26 days ago

Natera Announces Real-World Data Collaboration with Merck

Simply Wall St • 10 Nov 2023 • 08:00 am • 30 days ago

Is Natera (NASDAQ:NTRA) A Risky Investment?

Business Wire • 08 Nov 2023 • 08:00 am • 32 days ago

Natera Reports Third Quarter 2023 Financial Results

Yahoo Finance • 08 Nov 2023 • 08:00 am • 32 days ago

Natera Announces Randomized, Phase III TREAT ctDNA Trial in ...

Marketscreener.com • 07 Nov 2023 • 08:00 am • 33 days ago

Natera to Participate in November Investor Conferences -November ...

Nasdaq • 07 Nov 2023 • 08:00 am • 33 days ago

Enhabit (EHAB) Lags Q3 Earnings and Revenue Estimates

Financials for Natera Inc

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	2.6%	268,306,000	261,404,000	241,756,000	217,252,000	210,637,000	198,200,000	194,133,000	173,028,000	158,116,000	142,026,000	152,316,000	112,378,000	98,143,000	86,472,000	94,012,000	83,240,000	77,909,000	74,355,000	66,824,000	66,965,000	65,280,000
Costs and Expenses	1.5%	379,288,000	373,830,000	380,057,000	359,025,000	329,689,000	341,285,000	331,263,000	312,694,000	308,313,000	257,320,000	215,333,000	186,346,000	153,920,000	138,132,000	128,884,000	118,051,000	99,003,000	102,991,000	98,570,000	96,692,000	92,446,000
S&GA Expenses	1.5%	154,742,000	152,508,000	149,627,000	143,822,000	147,667,000	149,468,000	147,634,000	146,761,000	128,485,000	127,456,000	108,332,000	94,080,000	75,678,000	68,188,000	65,681,000	58,587,000	56,715,000	47,042,000	43,832,000	41,133,000	38,374,000
R&D Expenses	-1.2%	77,235,000	78,173,000	82,306,000	87,911,000	65,510,000	82,580,000	80,414,000	71,811,000	98,457,000	53,752,000	40,188,000	32,384,000	26,421,000	23,005,000	18,225,000	15,002,000	12,796,000	12,124,000	11,435,000	12,770,000	12,393,000
EBITDA Margin	8.8%	-0.47	-0.52	-0.59	-0.63	-0.67	-0.76	-0.79	-0.72	-0.68	-0.58	-0.52	-0.53	-0.46	-0.38	-0.30	-	-	-	-	-	-
Interest Expenses	2.4%	3,252,000	3,177,000	3,061,000	2,752,000	2,330,000	2,150,000	2,087,000	2,079,000	2,078,000	2,075,000	2,073,000	4,310,000	4,270,000	4,038,000	2,464,000	2,576,000	2,672,000	2,721,000	2,724,000	2,746,000	2,781,000
Income Taxes	171.6%	202,000	-282,000	160,000	443,000	185,000	193,000	179,000	-48,000	272,000	242,000	134,000	35,000	25,000	15,000	23,000	-14,000	44,000	1,895,000	74,000	-14,000	118,000
Earnings Before Taxes	2.0%	-108,828,000	-111,085,000	-136,777,000	-142,152,000	-121,295,000	-144,958,000	-138,416,000	-140,594,000	-151,001,000	-115,784,000	-63,719,000	-76,376,500	-58,298,000	-59,622,000	-35,349,000	-35,197,000	-23,093,000	-30,521,000	-34,017,000	-31,855,000	-29,498,000
EBT Margin	8.1%	-0.50	-0.55	-0.63	-0.67	-0.70	-0.79	-0.82	-0.75	-0.72	-0.62	-0.57	-0.59	-0.52	-0.45	-0.38	-	-	-	-	-	-
Net Income	1.6%	-109,030,000	-110,803,000	-136,937,000	-142,573,000	-121,480,000	-145,151,000	-138,595,000	-140,564,000	-151,273,000	-116,026,000	-63,853,000	-76,411,500	-58,323,000	-59,637,000	-35,372,000	-35,183,000	-23,137,000	-32,416,000	-34,091,000	-31,841,000	-29,616,000
Net Income Margin	8.1%	-0.51	-0.55	-0.63	-0.67	-0.70	-0.80	-0.82	-0.75	-0.72	-0.62	-0.57	-0.59	-0.52	-0.45	-0.38	-	-	-	-	-	-
Free Cashflow	55.7%	-38,656,000	-87,353,000	-92,488,000	-92,954,000	-114,457,000	-118,625,000	-153,162,000	-107,739,000	-104,197,000	-79,194,000	-85,136,000	-80,833,000	-35,073,000	-43,193,000	-43,017,000	-	-	-	-	-	-

Balance Sheet
(In Millions)

Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	15.9%	1,447	1,248	1,319	1,394	1,009	1,067	1,145	1,236	1,311	850	894	932	977	723	559	583	380	383	261	268	277
Current Assets	18.9%	1,267	1,066	1,129	1,212	830	902	980	1,093	1,191	740	791	863	916	664	497	523	324	322	208	241	249
Cash Equivalents	75.5%	669	381	403	466	57.00	91.00	159	85.00	95.00	63.00	65.00	49.00	210	77.00	74.00	62.00	52.00	30.00	35.00	51.00	39.00
Inventory	-1.4%	42.00	43.00	41.00	35.00	40.00	30.00	25.00	27.00	28.00	28.00	24.00	20.00	20.00	18.00	14.00	12.00	13.00	15.00	14.00	14.00	12.00
Net PPE	1.9%	105	103	101	92.00	87.00	82.00	78.00	66.00	59.00	49.00	40.00	33.00	28.00	26.00	27.00	23.00	19.00	22.00	23.00	24.00	25.00
Liabilities	1.6%	662	652	668	689	647	622	602	583	552	551	521	446	441	419	300	304	296	290	256	236	221
Current Liabilities	4.7%	290	277	291	310	267	252	231	219	200	198	167	199	196	176	177	180	138	127	113	114	102
Short Term Borrowings	0%	80.00	80.00	80.00	80.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00
Shareholder's Equity	31.6%	785	596	651	706	362	445	542	653	759	299	372	486	536	304	259	279	85.00	93.00	5.00	32.00	57.00
Retained Earnings	-5.0%	-2,299	-2,190	-2,079	-1,942	-1,800	-1,678	-1,533	-1,394	-1,254	-1,100	-986	-929	-852	-794	-734	-699	-663	-640	-699	-574	-542
Additional Paid-In Capital	10.5%	3,089	2,796	2,742	2,665	2,181	2,140	2,090	2,050	2,012	1,400	1,356	1,411	1,384	1,093	988	977	748	733	614	607	600
Shares Outstanding	4.3%	119	114	113	111	97.00	97.00	96.00	95.00	93.00	88.00	87.00	86.00	79.00	79.00	78.00	78.00	70.00	66.00	63.00	58.00	61.00

Cashflow (Last 12 Months)
(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	62.3%	-29.55	-78.39	-80.89	-81.13	-102	-110	-137	-98.74	-91.06	-70.56	-74.88	-73.30	-33.13	-40.98	-35.10	19.00	-48.39	-35.75	-31.82	-12.81	-23.27
Share Based Compensation	29.8%	58.00	44.00	41.00	36.00	40.00	41.00	35.00	30.00	26.00	35.00	23.00	16.00	15.00	12.00	7.00	2.00	20.00	10.00	4.00	4.00	4.00
Cashflow From Investing	72.5%	81.00	47.00	16.00	22.00	67.00	35.00	207	80.00	-431	60.00	87.00	-99.17	-110	-165	43.00	-151	-71.11	-100	13.00	22.00	-60.53
Cashflow From Financing	2434.4%	236	9.00	2.00	468	1.00	9.00	4.00	9.00	555	8.00	5.00	12.00	276	210	4.00	161	120	116	3.00	3.00	105

NTRA Income Statement

2023-09-30

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues
Total revenues	$ 268,306,000	$ 210,637,000	$ 771,466,000	$ 602,970,000
Cost and expenses
Research and development	77,235,000	65,510,000	237,714,000	228,504,000
Selling, general and administrative	154,742,000	147,667,000	456,877,000	444,769,000
Total cost and expenses	379,288,000	329,689,000	1,133,175,000	1,002,237,000
Loss from operations	(110,982,000)	(119,052,000)	(361,709,000)	(399,267,000)
Interest expense	(3,252,000)	(2,330,000)	(9,490,000)	(6,567,000)
Interest and other income, net	5,406,000	87,000	14,509,000	1,165,000
Loss before income taxes	(108,828,000)	(121,295,000)	(356,690,000)	(404,669,000)
Income tax expense	(202,000)	(185,000)	(80,000)	(557,000)
Net loss	(109,030,000)	(121,480,000)	(356,770,000)	(405,226,000)
Unrealized gain (loss) on available-for-sale securities, net of tax	3,807,000	(3,212,000)	10,966,000	(17,322,000)
Comprehensive loss	$ (105,223,000)	$ (124,692,000)	$ (345,804,000)	$ (422,548,000)
Net Loss per Share
Basic (in dollars per share)	$ (0.95)	$ (1.25)	$ (3.14)	$ (4.20)
Diluted (in dollars per share)	$ (0.95)	$ (1.25)	$ (3.14)	$ (4.20)
Weighted-average number of shares used in computing basic and diluted net loss per share:
Basic (in shares)	115,171	97,052	113,559	96,408
Diluted (in shares)	115,171	97,052	113,559	96,408
Product
Revenues
Total revenues	$ 265,218,000	$ 199,831,000	$ 761,271,000	$ 584,415,000
Cost and expenses
Cost of revenues	146,962,000	115,436,000	437,524,000	326,862,000
Licensing and other
Revenues
Total revenues	3,088,000	10,806,000	10,195,000	18,555,000
Cost and expenses
Cost of revenues	$ 349,000	$ 1,076,000	$ 1,060,000	$ 2,102,000

NTRA Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash, cash equivalents and restricted cash	$ 668,710	$ 466,091
Short-term investments	267,847	432,301
Accounts receivable, net of allowance of $6,034 and $3,830 at September 30, 2023 and December 31, 2022, respectively	255,147	244,385
Inventory	42,076	35,406
Prepaid expenses and other current assets, net	33,496	33,634
Total current assets	1,267,276	1,211,817
Property and equipment, net	104,830	92,453
Operating lease right-of-use assets	58,206	71,874
Other assets	16,208	18,330
Total assets	1,446,520	1,394,474
Current liabilities:
Accounts payable	21,321	31,148
Accrued compensation	39,415	44,010
Other accrued liabilities	133,740	144,214
Deferred revenue, current portion	15,012	10,777
Short-term debt financing	80,435	80,350
Total current liabilities	289,923	310,499
Long-term debt financing	282,619	281,653
Deferred revenue, long-term portion	21,033	20,001
Operating lease liabilities, long-term portion	68,287	76,577
Total liabilities	661,862	688,730
Commitments and contingencies (Note 8)
Stockholders' equity:
Common stock, $0.0001 par value: 750,000 shares authorized at both September 30, 2023 and December 31, 2022; 118,990 and 111,255 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	11	11
Additional paid in capital	3,089,448	2,664,730
Accumulated deficit	(2,299,405)	(1,942,635)
Accumulated other comprehensive loss	(5,396)	(16,362)
Total stockholders' equity	784,658	705,744
Total liabilities and stockholders' equity	$ 1,446,520	$ 1,394,474

About Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company's products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

CEO	Mr. Steven Leonard Chapman
WEBSITE	www.natera.com
EMPLOYEES	2958

Natera Inc Frequently Asked Questions

What is the ticker symbol for Natera Inc? What does NTRA stand for in stocks?

NTRA is the stock ticker symbol of Natera Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Natera Inc (NTRA)?

As of Fri Dec 08 2023, market cap of Natera Inc is 6.92 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NTRA stock?

You can check NTRA's fair value in chart. The fair value of Natera Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Natera Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NTRA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Natera Inc a good stock to buy?

The fair value guage provides a quick view whether NTRA is over valued or under valued. Whether Natera Inc is cheap or expensive depends on the assumptions which impact Natera Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NTRA.

What is Natera Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, NTRA's PE ratio (Price to Earnings) is -13.86 and Price to Sales (PS) ratio is 7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NTRA PE ratio will change depending on the future growth rate expectations of investors.

Market Summary

NTRA Alerts

NTRA Stock Price

NTRA RSI Chart

NTRA Alerts

NTRA Valuation

NTRA Price/Sales (Trailing)

NTRA Profitability

NTRA Fundamentals

NTRA Revenue

NTRA Earnings

Price Action

How does NTRA drawdown profile look like?

NTRA Financial Health

NTRA Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for NTRA

Which funds bought or sold NTRA recently?

Latest Funds Activity

Schedule 13G FIlings of Natera Inc

Recent SEC filings of Natera Inc

Peers (Alternatives to Natera Inc)

Natera Inc News

Financials for Natera Inc

Income Statement (Last 12 Months)

Balance Sheet.css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Cashflow (Last 12 Months)(In Millions)

NTRA Income Statement

NTRA Balance Sheet

About Natera Inc

Natera Inc Frequently Asked Questions

What is the ticker symbol for Natera Inc? What does NTRA stand for in stocks?

What is the market capital of Natera Inc (NTRA)?

What is the fair value of NTRA stock?

Is Natera Inc a good stock to buy?

What is Natera Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)